These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33361676)

  • 21. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
    Smid BE; van der Tol L; Cecchi F; Elliott PM; Hughes DA; Linthorst GE; Timmermans J; Weidemann F; West ML; Biegstraaten M; Lekanne Deprez RH; Florquin S; Postema PG; Tomberli B; van der Wal AC; van den Bergh Weerman MA; Hollak CE
    Int J Cardiol; 2014 Dec; 177(2):400-8. PubMed ID: 25442977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myocardial disease in inherited disease].
    Nakao S
    Nihon Rinsho; 2000 Jan; 58(1):200-3. PubMed ID: 10885314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac magnetic resonance imaging in patients with Fabry's disease.
    Małek LA; Chojnowska L; Spiewak M; Kłopotowski M; Miśko J; Petryka J; Miłosz B; Ruzyłło W
    Kardiol Pol; 2010 Aug; 68(8):929-34. PubMed ID: 20730727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
    Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
    Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
    Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
    Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of screening for Fabry disease among male dialysis patients.
    Ichinose M; Nakayama M; Ohashi T; Utsunomiya Y; Kobayashi M; Eto Y
    Clin Exp Nephrol; 2005 Sep; 9(3):228-32. PubMed ID: 16189631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
    Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
    Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
    Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
    Williams S; El-Medany A; Nightingale A; Ismail Y
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
    Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
    Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabry disease.
    Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
    J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
    Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
    Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fabry Disease and the Heart: A Comprehensive Review.
    Azevedo O; Cordeiro F; Gago MF; Miltenberger-Miltenyi G; Ferreira C; Sousa N; Cunha D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.